Biotech资产出海迎多重“大考”:交易条款里的长期挑战

研发客
Oct 29

//• 中国创新药企业在未来数年将面临许可合作全周期的多重考验。• 在欧美成熟市场,多数许可合作协议未能履行至协议期满,其中相当一部分在执行数年后即被提前终止,更有甚者因争议进入仲裁或诉讼程序。• 中国Biotech企业应充分认识到NewCo交易的“两步走”本质。•《美国优先投资政策》对中国创新药行业的实际影响,最终仍取决于落地的具体细则,中国Biotech行业应当密切关注动向。两周前,美参议院...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10